ClinicalTrials.gg
CompletedNCT02919995Updated May 21, 2024Results posted

A Study of RPL554 in Patients With Cystic Fibrosis

A Phase 2 interventional study of RPL554 and Placebo in Cystic Fibrosis, sponsored by Verona Pharma plc. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-21.

Sponsored by Verona Pharma plc (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Cystic Fibrosis by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Cystic Fibrosis · Merck & Co., Inc.

Enrollment
9th of 10
10 · median 68
Started
2017
the only one that year
Phase 2
6 of 10
none open now
Registered
10th of 10
by date

Among the 10 studies in Cystic Fibrosis by Merck & Co., Inc, this one is the 9th largest by enrollment, is the only one that started in 2017, is one of 6 in phase 2, and was the 10th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

None of the 10 studies in Cystic Fibrosis by Merck & Co., Inc is open now. The open studies under Cystic Fibrosis, anywhere →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Cystic Fibrosis by Merck & Co., Inc as a file.
02

Study summary

This study evaluates two doses of RPL554 and placebo in adult patients with cystic fibrosis. All patients receive all three treatments in a randomised sequence.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Sign an document indicating they understand the purpose of and procedures required for the study and are willing to participate in the study.

      1. Male or female aged ≥18 years at the time of informed consent. Females of must have been using a consistent and reliable form of (see Appendix 1) from the last menses before the first study treatment administration, and must commit to continue to do so during the study and for 3 months after the last dose of study treatment.
      1. Have a 12-lead recording at screening (Visit 1) and Visit 2 pre-dose showing the following:
      • Heart rate between 45 and 90 beats per minute
      • corrected for heart rate using Fridericia's formula (QTcF) interval ≤450 msec
      • QRS interval ≤120 msec
      • PR interval ≤220 msec
      • No abnormality including morphology (e.g. left bundle branch block, atrioventricular nodal dysfunction, ST segment abnormalities) 4. Capable of complying with all study restrictions and procedures including ability to use the study nebuliser correctly.

        1. (BMI) between 18 and 30 kg/m2 (inclusive) with a minimum weight of 40 kg.
        1. Patients with a genetic diagnosis of CF. 7. Spirometry at screening demonstrating an ≥40% and ≤80% of predicted normal.
        1. Capable of withdrawing from long acting bronchodilators1 until the end of the treatment period, and short acting bronchodilators for 8 hours prior to administration of study treatment.
        1. Clinically stable CF in the 2 weeks prior to randomisation (Visit 2).

Exclusion criteria

Exclusion Criteria:

  1. History of cirrhotic liver disease or portal hypertension.
  2. CF exacerbation requiring hospitalisation in the month prior to screening (Visit 1) or prior to randomisation (Visit 2).
  3. Use of oral or intravenous antibiotics (in additional to usual maintenance therapy) in the 2 weeks prior to screening (Visit 1) or randomisation (Visit 2).
  4. Other non-CF related respiratory disorders: Patients with a current diagnosis of active tuberculosis, lung cancer, sarcoidosis, sleep apnoea, known alpha-1 antitrypsin deficiency or other active pulmonary diseases.
  5. Previous lung resection or lung transplant.
  6. History of, or reason to believe a patient has, drug or alcohol abuse within the past 3 years.
  7. Received an experimental drug within 3 months or five half-lives, whichever is longer.
  8. Patients with a history of chronic uncontrolled disease including, but not limited to, cardiovascular (including arrhythmias), endocrine, active hyperthyroidism, neurological, hepatic, gastrointestinal, renal, haematological, urological, immunological or ophthalmic diseases that the Investigator believes are .
  9. Documented cardiovascular disease: angina, recent or suspected myocardial infarction, congestive heart failure, a history of unstable, or uncontrolled hypertension, or has been diagnosed with hypertension in last 3 months.
  10. Has had major surgery, (requiring general anaesthesia) in the 6 weeks prior to screening (Visit 1) or will not have fully recovered from surgery, or planned surgery through the end of the study.
  11. Infection with nontuberculous mycobacteria, methicillin-resistant Staphylococcus aureus (MRSA), or Burkholderia species.
  12. Use of immune-suppression; long term use of prednisolone ≥10 mg/day.
  13. History of of any organ system within 5 years with the exception of localised skin cancers (basal or squamous cell).
  14. Clinically significant abnormal values for safety laboratory tests (haematology, biochemistry or urinalysis) at screening (Visit 1), as determined by the Investigator.
  15. A disclosed history or one known to the Investigator, of significant non-compliance in previous studies or with prescribed medications.
  16. Requires oxygen therapy, even on an occasional basis.
  17. Pregnancy or lactation (female subjects only).
  18. Any other reason that the Investigator considers makes the patient unsuitable to participate. -
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Higher Dose RPL554

    Single dose of inhaled 6 mg RPL554

    Drug: RPL554

  • Experimental
    Lower dose RPL554

    Single dose of inhaled 1.5 mg RPL554

    Drug: RPL554

  • Placebo comparator
    Placebo

    Inhaled placebo dose

    Drug: Placebo

Interventions

  • DrugRPL554

    RPL554 suspension administered using a nebuliser

  • DrugPlacebo

    Placebo solution administered using a nebuliser

06

What researchers measure

Primary outcomes

  1. AUC by Dose

    Area under the curve (AUC)

    Time frame: Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose after each treatment

  2. Maximum Plasma Concentration After Each Dose

    Maximum plasma concentration (Cmax) after a single dose of RPL554

    Time frame: Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose

  3. Time to Maximum Plasma Concentration After Each Dose

    Time to maximum concentration (Tmax) after a single dose of RPL554

    Time frame: Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose

  4. Half Life for Each Dose

    Half life (t1/2) of RPL554

    Time frame: Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose

Secondary outcomes

  1. Peak FEV1 for Each Treatment

    Maximum Forced expired volume in one second (FEV1) measured using spirometry

    Time frame: Pre dose and 15 and 30 minutes and 1, 2 and 4 hours post dose after treatment

  2. AUC FEV1(0-4h)

    Area under the curve for FEV1 over 4 hours measured using spirometry

    Time frame: Pre dose and 15 and 30 minutes and 1, 2 and 4 hours post dose

  3. AUC FEV1(0-6h)

    Area under the curve FEV1 over 6 hours measured using spirometry

    Time frame: Pre dose and 15 and 30 minutes and 1, 2, 4 and 6 hours post dose

  4. AUC FEV1(0-8h)

    Area under the curve for FEV1 over 8 hours measured using spirometry

    Time frame: pre dose and 15 and 30 minutes and 1, 2, 4, 6 and 8 hours post dose

  5. FVC

    Forced vital capacity (FVC) measured using spirometry

    Time frame: Over 24 hours after treatment

  6. Breath Samples

    Exhaled breath pH

    Time frame: 8 and 24 hours after treatment

  7. Laboratory Safety Tests 1

    Biochemistry panel parameters

    Time frame: Screening and end of study

  8. Laboratory Safety Tests 2

    Haematology panel parameters

    Time frame: Screening and end of study

  9. Laboratory Safety Tests 3

    Urinalysis measured by urine dipstick

    Time frame: Screening and end of study

  10. Vital Signs 1

    Pulse rate after 5 minutes supine

    Time frame: Over 8 hours after treatment

  11. Vital Signs 2

    Blood pressure after 5 minutes supine

    Time frame: Over 8 hours after treatment

  12. ECG 1

    Heart rate

    Time frame: Over 8 hours after treatment

  13. ECG 2

    QT interval

    Time frame: Over 8 hours after treatment

Other outcomes

  1. Sputum Rheology

    Rheological analysis for interleukin 8, tumour necrosis factor alpha and myeloperoxidase

    Time frame: 8 and 12 hours after treatment

  2. Sputum Measurements

    Levels of inflammatory mediators

    Time frame: 8 and 12 hours after treatment

07

Results

Posted Mar 20, 2019

Participant flow

Participant flow — Overall Study
MilestoneHigher Dose RPL554/Lower Dose RPL554/PlaceboLower Dose RPL554/Placebo/Higher Dose RPL554Higher Dose RPL554/Plaebo/Lower Dose RPL554Lower Dose RPL554/Higher Dose RPL554/PlaceboPlacebo/Higher Dose RPL554/Lower Dose RPL554Placebo/Lower Dose RPL554/Higher Dose RPL554
Started122212
Completed122211
Not completed000001
Withdrew: Adverse event000001

Outcome measures

PrimaryAUC by Dose

Area under the curve (AUC)

Time frame:
Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose after each treatment
Reported as:
Mean · pg*h/mL
AUC by Dose
pg*h/mLHigher Dose RPL554Lower Dose RPL554
AUC by Dose7699 ± 2965.72342 ± 1029.9
PrimaryMaximum Plasma Concentration After Each Dose

Maximum plasma concentration (Cmax) after a single dose of RPL554

Time frame:
Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose
Reported as:
Mean · pg/mL
Maximum Plasma Concentration After Each Dose
pg/mLHigher Dose RPL554Lower Dose RPL554
Maximum Plasma Concentration After Each Dose828.3 ± 256.1270.1 ± 91.9
PrimaryTime to Maximum Plasma Concentration After Each Dose

Time to maximum concentration (Tmax) after a single dose of RPL554

Time frame:
Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose
Reported as:
Mean · hours
Time to Maximum Plasma Concentration After Each Dose
hoursHigher Dose RPL554Lower Dose RPL554
Time to Maximum Plasma Concentration After Each Dose1.53 ± 0.661.33 ± 0.62
PrimaryHalf Life for Each Dose

Half life (t1/2) of RPL554

Time frame:
Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose
Reported as:
Mean · Hours
Half Life for Each Dose
HoursHigher Dose RPL554Lower Dose RPL554
Half Life for Each Dose10.14 ± 3.17.52 ± 3.3
SecondaryPeak FEV1 for Each Treatment

Maximum Forced expired volume in one second (FEV1) measured using spirometry

Time frame:
Pre dose and 15 and 30 minutes and 1, 2 and 4 hours post dose after treatment
Reported as:
Mean · Liters
Peak FEV1 for Each Treatment
LitersHigher Dose RPL554Lower Dose RPL554Placebo
Peak FEV1 for Each Treatment2.384 ± 0.732.247 ± 0.722.256 ± 0.71
Statistical analysis
  • Lower Dose RPL554 vs Placebo · ANCOVA · p = 0.0196 · Contrast ratio: 1.038 · 95% CI 1.007 to 1.07
  • Higher Dose RPL554 vs Placebo · ANCOVA · p = 0.0802 · Contrast ratio: 1.024 · 95% CI 0.997 to 1.052
  • Higher Dose RPL554 vs Lower Dose RPL554 · ANCOVA · p = 0.3487 · Contrast ratio: 0.986 · 95% CI 0.957 to 1.017
SecondaryAUC FEV1(0-4h)

Area under the curve for FEV1 over 4 hours measured using spirometry

Time frame:
Pre dose and 15 and 30 minutes and 1, 2 and 4 hours post dose
Reported as:
Mean · Liters
AUC FEV1(0-4h)
LitersHigher Dose RPL554Lower Dose RPL554Placebo
AUC FEV1(0-4h)2.313 ± 0.732.194 ± 0.722.133 ± 0.73
Statistical analysis
  • Lower Dose RPL554 vs Placebo · ANCOVA · p = 0.0043 · Contrast ratio: 1.072 · 95% CI 1.026 to 1.12
  • Higher Dose RPL554 vs Placebo · ANCOVA · p = 0.0109 · Contrast ratio: 1.055 · 95% CI 1.014 to 1.096
  • Higher Dose RPL554 vs Lower Dose RPL554 · ANCOVA · p = 0.4306 · Contrast ratio: 0.984 · 95% CI 0.942 to 1.027
SecondaryAUC FEV1(0-6h)

Area under the curve FEV1 over 6 hours measured using spirometry

Time frame:
Pre dose and 15 and 30 minutes and 1, 2, 4 and 6 hours post dose
Reported as:
Mean · Liters
AUC FEV1(0-6h)
LitersHigher Dose RPL554Lower Dose RPL554Placebo
AUC FEV1(0-6h)2.304 ± 0.742.188 ± 0.732.133 ± 0.73
Statistical analysis
  • Lower Dose RPL554 vs Placebo · ANCOVA · p = 0.0064 · Contrast ratio: 1.065 · 95% CI 1.021 to 1.11
  • Higher Dose RPL554 vs Placebo · ANCOVA · p = 0.0149 · Contrast ratio: 1.049 · 95% CI 1.011 to 1.089
  • Higher Dose RPL554 vs Lower Dose RPL554 · ANCOVA · p = 0.466 · Contrast ratio: 0.945 · 95% CI 0.945 to 1.027
SecondaryAUC FEV1(0-8h)

Area under the curve for FEV1 over 8 hours measured using spirometry

Time frame:
pre dose and 15 and 30 minutes and 1, 2, 4, 6 and 8 hours post dose
Reported as:
Mean · Liters
AUC FEV1(0-8h)
LitersHigher Dose RPL554Lower Dose RPL554Placebo
AUC FEV1(0-8h)2.287 ± 0.752.185 ± 0.742.130 ± 0.74
Statistical analysis
  • Lower Dose RPL554 vs Placebo · ANCOVA · p = 0.0093 · Contrast ratio: 1.061 · 95% CI 1.017 to 1.107
  • Higher Dose RPL554 vs Placebo · ANCOVA · p = 0.0333 · Contrast ratio: 1.042 · 95% CI 1.004 to 1.082
  • Higher Dose RPL554 vs Lower Dose RPL554 · ANCOVA · p = 0.3693 · Contrast ratio: 0.982 · 95% CI 0.941 to 1.024
SecondaryFVC

Forced vital capacity (FVC) measured using spirometry

Time frame:
Over 24 hours after treatment

Results for this outcome have not been posted.

SecondaryBreath Samples

Exhaled breath pH

Time frame:
8 and 24 hours after treatment

Results for this outcome have not been posted.

SecondaryLaboratory Safety Tests 1

Biochemistry panel parameters

Time frame:
Screening and end of study

Results for this outcome have not been posted.

SecondaryLaboratory Safety Tests 2

Haematology panel parameters

Time frame:
Screening and end of study

Results for this outcome have not been posted.

SecondaryLaboratory Safety Tests 3

Urinalysis measured by urine dipstick

Time frame:
Screening and end of study

Results for this outcome have not been posted.

SecondaryVital Signs 1

Pulse rate after 5 minutes supine

Time frame:
Over 8 hours after treatment

Results for this outcome have not been posted.

SecondaryVital Signs 2

Blood pressure after 5 minutes supine

Time frame:
Over 8 hours after treatment

Results for this outcome have not been posted.

SecondaryECG 1

Heart rate

Time frame:
Over 8 hours after treatment

Results for this outcome have not been posted.

SecondaryECG 2

QT interval

Time frame:
Over 8 hours after treatment

Results for this outcome have not been posted.

Other pre-specifiedSputum Rheology

Rheological analysis for interleukin 8, tumour necrosis factor alpha and myeloperoxidase

Time frame:
8 and 12 hours after treatment

Results for this outcome have not been posted.

Other pre-specifiedSputum Measurements

Levels of inflammatory mediators

Time frame:
8 and 12 hours after treatment

Results for this outcome have not been posted.

Adverse events

Collected over From informed consent through study completion, up to 52 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Higher Dose RPL5540/9 (0%)0/9 (0%)6/9 (66.7%)
Lower Dose RPL5540/10 (0%)1/10 (10%)6/10 (60%)
Placebo0/10 (0%)0/10 (0%)3/10 (30%)
Most frequent serious events
Most frequent serious events
EventHigher Dose RPL554Lower Dose RPL554Placebo
exacerbation of cystic fibrosisInfections and infestations0/91/100/10
Most frequent other events
Showing 10 of 16
Most frequent other events
EventHigher Dose RPL554Lower Dose RPL554Placebo
TachycardiaCardiac disorders2/92/101/10
CoughRespiratory, thoracic and mediastinal disorders2/91/100/10
Forced expiratory volume decreasedInvestigations1/90/100/10
RhinorrhoeaRespiratory, thoracic and mediastinal disorders1/90/100/10
Chest discomfortGeneral disorders1/91/100/10
NauseaGastrointestinal disorders1/90/100/10
Oral candidiasisInfections and infestations1/90/100/10
Pulmonary function test decreasedInvestigations0/91/101/10
Drug hypersensitivityImmune system disorders0/91/100/10
Nasal congestionRespiratory, thoracic and mediastinal disorders0/90/101/10

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Higher Dose RPL554/Lower Dose RPL554/PlaceboLower Dose RPL554/Placebo/Higher Dose RPL554Higher Dose RPL554/Placebo/Lower Dose RPL554Lower Dose RPL554/Higher Dose RPL554/PlaceboPlacebo/Higher Dose RPL554/Lower Dose RPL554Placebo/Lower Dose RPL554/Higher Dose RPL554Total
<=18 years0000000
Between 18 and 65 years12221210
>=65 years0000000
Sex: Female, Male
Sex: Female, Male(Participants)Higher Dose RPL554/Lower Dose RPL554/PlaceboLower Dose RPL554/Placebo/Higher Dose RPL554Higher Dose RPL554/Placebo/Lower Dose RPL554Lower Dose RPL554/Higher Dose RPL554/PlaceboPlacebo/Higher Dose RPL554/Lower Dose RPL554Placebo/Lower Dose RPL554/Higher Dose RPL554Total
Female0021014
Male1201116
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Higher Dose RPL554/Lower Dose RPL554/PlaceboLower Dose RPL554/Placebo/Higher Dose RPL554Higher Dose RPL554/Placebo/Lower Dose RPL554Lower Dose RPL554/Higher Dose RPL554/PlaceboPlacebo/Higher Dose RPL554/Lower Dose RPL554Placebo/Lower Dose RPL554/Higher Dose RPL554Total
American Indian or Alaska Native0000000
Asian0000000
Native Hawaiian or Other Pacific Islander0000000
Black or African American0000000
White12221210
More than one race0000000
Unknown or Not Reported0000000
08

Study locations

1 site
  • Papworth Hospital
    Cambridge, CB23 3RE, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Nov 2017, 8 months.

Results were first posted in Mar 2019, 1 year 4 months after primary completion.

Of 40 industry-sponsored phase 2 interventional studies under Cystic Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 8 months is below that.

Counting every sponsor, half of 57 studies reached it within 21 months; a quarter within 9 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2016
First posted
Sep 30, 2016
StartActual
Feb 8, 2017
Primary completionActual
Nov 3, 2017
CompletionActual
Nov 3, 2017
Results first posted
Mar 20, 2019
Last update
May 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02919995
Lead sponsor
Verona Pharma plc
Collaborators
Cystic Fibrosis Trust
Responsible party
Sponsor
First posted
Sep 30, 2016
Start date
Feb 8, 2017
Primary completion
Nov 3, 2017
Completion
Nov 3, 2017
Results posted
Mar 20, 2019
Last update
May 21, 2024

Study contacts

Andres Floto
principal investigator · Cambridge Centre for Medical Research, Papworth Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ensifentrine

Start the discussion